Formal and informal pharmaceutical economies in Third World countries: Synergetic, symbiotic or parasitical?

Crime, Law and Social Change

Volumn 45, Issue 4-5, 2006, Pages 361-372

  Vande Walle, Gudrun ^a   Ponsaers, Paul ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33845489127     PISSN: 09254994     EISSN: 15730751     Source Type: Journal    
DOI: 10.1007/s10611-006-9039-z     Document Type: Article

References (35)

1. Bledsoe, C., & Goubaud, M. (1985). The reinterpretation and distribution of western pharmaceuticals: An example from the Mende of Sierra Leone. In S. Van Der Geest & S. Reynolds Whyte (Eds.), The context of medicines in developing countries. Studies in pharmaceutical anthropology. Amsterdam: Het Spinhuis.
2. Braithwaite, J. (1984). Corporate crime in the pharmaceutical industry. London: Routledge and Kegan Paul.
3. Braithwaite, J., & Drahos, P. (2000). Global business regulation. Cambridge: Cambridge University Press.
4. Castells, M., & Portes, A. (1989). World underneath: The origins, dynamics, and effects of the informal economy. In M. Castells & A. Portes (Eds.), The informal economy. Studies in advanced and less developed countries (p. 12). London: The John Hopkins University Press.
5. Chetley, A. (1993). Problem drugs. Amsterdam: Health Action International.
6. Curti, A. (2001). The WTO dispute settlement understanding: An unlikely weapon in the fight against AIDS. American Journal of Law and Medicine, 27, 469-485.
7. Dallago, B. (1990). The irregular economy (p. 7). Dartmouth: Aldershot.
8. EFPIA, counterfeiting medicines, (electr.copy: http://www.efpia.org/ 2_indust/counterfeitdrugs.pdf).
9. Guillaume, M. (2003). Antiretroviral medicines and the informal market in Senegal: Does the governmental antiretroviral access programme have a controlling effect? IRD - Scientific Bulletins, 166.
10. Harding, P., & Jenkins, R. (1989). The myth of hidden economy. Towards a new understanding of informal economic activity (pp. 15-16). Milton Keynes: Open University Press.
11. Logan, K. (1988). Casi como doctor: Pharmacists and their clients in a Mexican urban context. In S. Van Der Geest & S. Reynolds Whyte (Eds.), The context of medicines in developing countries. Studies in pharmaceutical anthropology. Amsterdam: Het Spinhuis, p. 125.
12. Lund, F., & Skinner, C. (2005). Local government innovations for the informal economy. Development Outreach, Worldbank, March 2005 (electr.copy: http://www1.worldbank.org/devoutreach).
13. Morris, J., & Stevens, P. (2006). Counterfeit medicines in less developed countries. Problems and Solutions. London: International Policy Network.
14. Neef, R. (2002). Observations on the concept and forms of the informal economy in eastern Europe. In R. Neef & M. Stanculescu (Eds.), The social impact of informal economies in eastern Europe (pp. 1 and 6). London: Ashgate.
15. Niehof, A. (1988). Traditional medication at pregnancy and childbirth in Madura, Indonesia. In S. Van Der Geest & S. Reynolds Whyte (Eds.), The context of medicines in developing countries. Studies in pharmaceutical anthropology. Amsterdam: Het Spinhuis.
16. Nsarhaza, K., (1997). Au-delà de la regulation étatique: La gouvernance du marché informel de la santé: Cas des medicaments au Zaïre. Geneva: UNRISD.
17. Nsarhaza, K. (1998). The informal pharmaceuticals market in the democratic republic of Congo. Development in Practice, 8(2), 243.
18. Oxfam (2001). A summary of the final act of the Uruguay Round of Multilateral Trade negotiations of 15 April 1994.
19. Oxfam (2001). Cut the cost. Patent injustice: How world trade rules threaten the health of poor people. London: Oxfam.
20. Oxfam (2001). Oxfam policy paper, WTO patent rules and access to medicines: The pressure mounts, (electr.copy: http://www.oxfam.org.uk/policy/ papers/wtorules/wtorules.htm).
21. Oxfam (2004). Free trade agreement between the USA and Thailand threatens access to HIV/AIDS treatment, Oxfam briefing note, July 2004.
22. Pai, S. A., Lakshmi, P. K., Rao, B. C., & Sahni P. (2003). Pharmaceutical companies and the third world. The Lancet, 361(9363), 1136-1137 (29 March).
23. Pichlbauer, K., Pastor, U., Rasti, Z., Schaaber, J., Tuschinsky, C., et al. (1999). German drugs. Poor choices for poor countries. Bielefeld: BUKO Pharma-Kampagne.
24. Rath, J. (1995). Beunhazen van buitende informele economic als bastaardsfeer van sociale integratie. In G. Engbersen & R. Garbiëls (Eds.), Sferen van integratie. Naar een gedifferentieerd allochtonenbeleid (p. 78). Meppel/Amsterdam: Boom.
25. Richter, J. (2001). Holding corporations accountable. Corporate conduct, international codes and citizen action (p. 18). London: Zed Books.
26. Rozendaal, J. (2001). Fake antimalaria drugs in Cambodia, The Lancet, 357, 890.
27. Ruggiero, V. (2000). Crime and the markets. Essays in anti-criminology. New York: Oxford University Press.
28. Sassen, S. (1991). The informal economy. In Y. Mollenkopf & M. Castells (Eds.), Dual city. Restructuring New York. New York: The Russell Sage Foundation.
29. Siringi, S. (2004). AIDS drugs being sold illegally on market stalls in Kenya. The Lancet, 57(363:9406), January 2004.
30. Van Der Geest, S. (1984) Anthropology and pharmaceuticals in developing countries. Medical Anthropology Quarterly, 15(3), 59-62.
31. Van Der Geest, S. (1988). The articulation of formal and informal medicine distribution in South Cameroon. In S. Van Der Geest & S. Reynolds Whyte (Eds.), The context of medicines in developing countries. Studies in pharmaceutical anthropology. Amsterdam: Het Spinhuis.
32. Van Der Geest, S., Whyte Reynolds, S., & Hardon, A. (1988). The anthropology of pharmaceuticals: A biographical approach. Annual Review of Anthropology, 25.
33. WHO (2006) Counterfeit medicines (fact sheet no. 275), February.
34. Wolffers, I. (1988). Traditional practitioners and western pharmaceuticals in Sri Lanka. In S. Van Der Geest & S. Reynolds Whyte (Eds.), The context of medicines in developing countries. Studies in pharmaceutical anthropology (p. 53). Amsterdam: Het Spinhuis.
35. Zakrzewski, P. (2002). Bioprospecling or biopiracy? The pharmaceutical industry's use of indigenous medicinal plants as a source of potential drug candidates. University of Toronto Medical Journal, 79(3), 252.